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Abstract 
The syndrome of primary aldosteronism (PA) is characterized by hypertension with 
excessive, autonomous aldosterone production and is usually caused by either a 
unilateral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia 
(BAH). The diagnostic workup of PA is a sequence of three phases comprising 
screening tests, confirmatory tests and the differentiation of unilateral from bilateral 
forms. The latter step is necessary to determine the optimal treatment approach of 
unilateral laparoscopic adrenalectomy (for patients with unilateral PA) or medical 
treatment with a mineralocorticoid receptor antagonist (for patients with bilateral 
PA). Since the publication of the revised Endocrine Society guideline 2016 a number 
of key studies have been published. They challenge the recommendations of the 
guideline in some areas and confirm current practice in others. Herein we present 
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Introduction 
Primary aldosteronism (PA), first described by Jerome W. Conn in 1955, was once 
thought to be a rare condition of hypertension characterized by hypokalemia and 
excess aldosterone production relative to suppressed plasma renin (1). The 
application of the current screening method of an elevated plasma aldosterone-to-
renin ratio (ARR) to a wider target population (instead of restricted to patients with 
hypokalemia) accounting for up to 50% of the population with hypertension has 
greatly increased the diagnosis of PA (2). It is now widely accepted that this 
syndrome is the most common form of endocrine hypertension. PA is specifically 
treated by unilateral adrenalectomy (preferably by laparoscopic surgery) or 
pharmacologically with a mineralocorticoid receptor (MR) antagonist that 
competitively inhibits the binding of aldosterone to the MR (3).  
 
Patients with PA have an increased risk of cardiovascular and cerebrovascular events 
and target organ damage (heart and kidney) relative to patients with essential 
hypertension and a matched cardiovascular risk profile (4-7) or compared with the 
general population with hypertension (8). Patients with PA also display an increased 
prevalence of metabolic syndrome and diabetes (4, 9-11), osteoporotic fractures (12) 
and symptoms of depression with a reduced quality of life (13-14). Some of these 
comorbidities may be associated with cortisol co-secretion (15). All available 
evidence indicates that an early diagnosis and appropriate clinical management 
(surgical or medical) is mandatory to minimize the increased risks associated with PA 
(5, 16-18).  
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The diagnostic management of PA comprises three phases: screening tests, case 
confirmation and differentiation of unilateral from bilateral forms of PA for 
therapeutic decision-making and appropriate treatment (Figure 1).  
 
Diagnosis: Screening 
Measurement of plasma aldosterone concentrations (PAC) and plasma renin activity 
(PRA) or the direct renin concentration (DRC) to assess the ARR is the most reliable 
currently available method of screening for PA. The Endocrine Society (ES) Clinical 
Practice Guideline recommends screening patients with an increased likelihood of PA 
(Table 1) (3). It has been suggested that all patients with hypertension should be 
screened for PA (19), based on the findings of the prospective PATO study (8) which 
reported a 5.9% prevalence of PA in 1672 unselected patients with hypertension in 
primary care (8). However, evidence that a systematic screening approach 
(compared with selective screening) results in a reduction of morbidity, mortality 
and cardiovascular disease of patients with hypertension to an extent that would 
justify the increased costs and burden on health systems is lacking. 
 
To screen for PA by the ARR, it is recommended that medications interfering with 
the renin-angiotensin system, and specifically those that may stimulate renin 
secretion, should be withdrawn (this applies throughout the diagnostic workup for 
PA because other tests and procedures also rely on measurements of steroids under 
conditions of suppressed renin). Antihypertensive medication that interferes with 
the ARR includes diuretics (including spironolactone) and should be withdrawn for 4 
weeks. Other drugs that should be withdrawn, but for a lesser period of 2 weeks 
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prior to testing, are β-blockers, clonidine, methyldopa, non-steroidal anti-
inflammatory drugs, ACE inhibitors, angiotensin receptor blockers and 
dihydropyridine calcium blockers (3, 20). However, in many instances, interpretation 
of the ARR is confidently possible without changing interfering medications. Non-
dihydropyridine long-acting calcium channel blockers (verapamil or diltiazem), the 
vasodilator hydralazine and α1-adrenergic receptor blockers have limited or no 
effects on the ARR compared to the above and are suggested to control 
hypertension in those patients with elevated blood pressure requiring medical 
treatment (3, 20). As a caveat, severe deleterious side-effects have been reported by 
adjustment of antihypertensive therapy in accordance with the ES Guideline during 
screening for PA (21). In our center more than 90% of patients receive adjusted 
medication according to the ES guideline during screening, and serious adverse 
events have been reduced to a minimum after appropriate exclusion of high risk 
patients. 
 
Before performing the ARR screening test, patients should avoid a low salt diet and 
have a minimum intake of 5g NaCl/day. Hypokalemia, if present, should be 
corrected. To allow activation of the renin-angiotensin system, blood samples are 
withdrawn in the morning when patients have been out of bed for ≥ 2 h. The assay 
characteristics and the use of different available commercial assays for the 
measurement of PAC, PRA or DRC can highly influence the ARR (22). The method-
dependence of aldosterone and renin measurements has contributed to the lack of a 
standardized cut-off value for ARR screening and the wide variability in upper 
reference limits used across centers.  The Japan ES Guidelines recommend a specific 
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cut-off for the ARR (ARR > 200 with PAC in pg/mL and PRA in ng/mL/hr and indicate 
that the risk of PA increases with PAC > 120-150 pg/mL) with a specific commercially 
available assay (23). Radioimmunoassays are widely employed for the measurement 
of plasma PAC, PRA or DRC but assays using chemiluminescence have been shown to 
be reliable alternatives (24-26) using simultaneous assays for PAC and DRC (24). 
 
An elevated ARR can result if the PRA (or DRC) is very low even if the PAC is low-
normal and inconsistent with PA. Some centers do not proceed with the diagnostic 
workup of PA of such patients and require a minimum PAC in addition to an elevated 
ARR for a positive screening test. At least, baseline PAC should be higher than the 
normal range of confirmatory tests, as discussed later (20). 
 
Diagnosis: Confirmatory Testing 
Confirmatory testing is considered mandatory by the ES Guideline for a definitive 
diagnosis of PA. An exception is in evident cases of PA with spontaneous 
hypokalemia and a PAC > 20 ng/dL (550 pmol/L)] with PRA (or DRC) below assay 
detection limits (3).  Confirmation or exclusion of the diagnosis of PA is performed by 
≥1 confirmatory tests as recommended by the ES Guideline (3).  
 
Confirmatory tests demonstrate the inappropriate production of aldosterone in 
response to exogenously administered agents that normally completely suppress or 
inhibit circulating angiotensin II levels (the endogenous positive regulator of 
aldosterone production). The test thereby confirms that aldosterone production is 
autonomous of the renin-angiotensin-system. 
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Potassium is a key regulator of aldosterone production and hypokalemia (if present) 
should be corrected with slow-release KCl tablets prior to confirmatory testing 
because failure to do so may produce a false-negative result. Since sodium chloride 
infusion during confirmatory testing may further deteriorate plasma potassium 
levels we administer KCl tablets even in patients with low normal potassium levels. 
Stress-induced increases of ACTH - indicated by an increase in plasma cortisol 
concentration - can interfere with aldosterone suppression and produce a false-
positive test result. Consequently, cortisol levels should be monitored during 
confirmatory testing, and the aldosterone response interpreted with caution if 
increased cortisol levels indicate inappropriate stress at the end of the test. 
 
The most commonly employed suppression tests use saline loading (either by 
intravenous infusion or orally), fludrocortisone (FST) or a captopril challenge (Table 
2). Confirmatory testing based on saline loading are widely in use because they are 
straight forward and reliable and have low costs but saline loading by infusion (2 L 
i.v. infusion of 0.9% NaCl over 4h) or oral sodium intake (6g/day for 3 days, 
aldosterone measured in a 24 h urine collection over days 3 to 4) carry the risk of 
acute volume overload especially in those predisposed by left ventricular or renal 
dysfunction. The saline infusion test has a sensitivity of 83% using a cut-off of < 6.8 
ng/dL (188 pmol/L) (27) and 88% using a cut-off of <5.0 ng/dL (<139 pmol/L) (28). A 
recent study suggested that up to 29% of patients with PA with suppressed 
aldosterone below 5.0 ng/dL (139 pmol/L) were patients with unilateral  
aldosteronism and candidates for surgery (29). The authors suggest that patients 
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with an elevated ARR and elevated basal aldosterone concentrations may directly 
undergo AVS without a suppression test, a strategy also proposed in the recently 
published guideline for patients with hypokalemia (3).  The sensitivity of the saline 
infusion test is reportedly increased by performing the test in the seated position 
(29-31). The captopril challenge test (25-50 mg orally administered captopril after 
sitting or standing for > 1 h) is likewise easily performed and circumvents potential 
fluid overload in patients who are at risk due to compromised renal or cardiac 
function. The FST requires the consumption of fludrocortisone with sodium and 
potassium supplementation and up to 5-days hospitalization to ensure control of 
blood pressure and plasma potassium concentrations that must be closely 
monitored throughout the test because of the risk of hypokalemia. Proponents of 
the FST highlight the safety of the test in expert hands with a superior sensitivity 
compared with other methods [a detailed protocol is described in Stowasser & 
Gordon (20)]. The test is nonetheless unfeasible in most countries because of cost 
limitations imposed by the requirement for several days’ hospitalization.  
 
Diagnosis: Subtype Differentiation 
Subtype diagnosis begins with the exclusion of patients with a rare form of PA 
caused by an aldosterone-producing carcinoma using an imaging technique such as 
computed tomography (CT) scanning, or magnetic resonance imaging (MRI)]. The 
value of CT scanning and MRI have been questioned since they might not faithfully 
distinguish the source of aldosterone excess and micro-APAs (≤ 10 mm in diameter) 
are often undetectable by current imaging methods (32-33). In addition, the 
proportion of patients with adrenal incidentalomas increases with age leading to 
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false positive imaging findings and reduced specificity. Therefore, the ES guideline 
issued a strong recommendation to perform AVS in every patient who is a candidate 
for surgery to reliably differentiate unilateral from bilateral PA.  
 
Blood samples are obtained for steroid measurements from the right and left 
adrenal veins to determine if the overproduction of aldosterone originates from a 
unilateral or bilateral source (Figure 2). Some experts recommend AVS in all patients 
with confirmed PA (34), others consider predictors of unilateral disease and patient 
preference (35, 36). According to the ES Guideline, young patients (< 35 years) with 
imaging findings of a unilateral adenoma (> 10 mm and a normal appearing 
contralateral adrenal) can bypass AVS if they display a marked phenotype (for 
example, PAC > 30 ng/dL [831 pmol/L] and spontaneous hypokalemia at baseline) 
(3). Although selecting patients to bypass AVS and proceed to surgery on the basis of 
young age, imaging results and PA phenotype has been reported to lack specificity 
(37), data from a multicentric study in Japan reported that factors based on young 
age and specific imaging and biochemical characteristics as recommended by the ES 
guideline could accurately predict unilateral disease (38).  
 
In preparation for AVS, antihypertensive medication that interferes with the renin-
angiotensin system, specifically by stimulating renin secretion, should be withdrawn. 
Loop and thiazide diuretics, amiloride, and MR antagonists should be interrupted 4 
weeks before AVS and substituted for antihypertensive medication with less (or 
minimal) effects on renin secretion such as α1-adrenergic receptor blockers and 
non-dihydropyridine long-acting calcium channel blockers (verapamil or diltiazem). If 
Page 9 of 32
 8 
plasma renin activity or concentration is suppressed, AVS can be performed 
irrespective of the time of drug withdrawal (39) and, in exceptional cases, MR 
antagonist therapy can be continued during AVS if renin remains suppressed (40). 
 
The success of AVS, determined by the correct cannulation of the adrenal veins, is 
measured by the selectivity index (SI) which is calculated as the ratio of cortisol in 
the adrenal vein and in a peripheral vein. The cannulation of the adrenal veins is 
particularly challenging on the right side because of anatomical differences between 
the right and left adrenal veins (Figure 2). Success rates differ greatly but can be 
improved by a rapid cortisol assay to ascertain when resampling is necessary if the 
AVS was unsuccessful (41, 42). The use of such an assay has increased the proportion 
of successful AVS from 55% to 85% in the experience of one referral center largely 
due to an increased successful cannulation of the right adrenal vein (43). The 
lateralization of aldosterone production is usually calculated by the lateralization 
index (LI) although the LI is sometimes considered together with a requirement for 
contralateral suppression of aldosterone production to define lateralization (Table 3, 
Table 4). There is no standardized cut-off for the SI, or indeed for any of the indices 
used in AVS. Although there have been attempts to standardize AVS protocols (39, 
44), the reference limits remain arbitrary to some extent and the interpretation of 
AVS results vary widely across centers (Table 4).  
 
AVS is performed in the morning when ACTH-stimulated aldosterone production is 
maximal following at least 1 h recumbency to avoid the effects of postural changes 
on the stimulation of the renin-angiotensin-system. An AVS procedure with an 
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exogenously administered synthetic derivative of ACTH (ACTH 1-24, called 
cosyntropin) is used by some for various reasons that include increasing technical 
success rates, stimulating the production of aldosterone from APAs and minimizing 
variations in cortisol and aldosterone production caused by stress-induced ACTH 
release during non-simultaneous AVS. Although some concerns have been raised on 
the possible stimulation of aldosterone production from the contralateral adrenal 
gland (non-dominant gland) in unilateral PA, AVS with ACTH infusion can improve 
the technical success rate of AVS (45, 46) and can perform as well as unstimulated 
protocols with ACTH administered as a bolus (usually 0.25 mg [10 IU]) or continuous 
infusion (initiated 30 min before the procedure [50 µg/h]) performing equally well 
(47). The effects of ACTH stimulation were illustrated by a study in which a bolus of 
250 µg of ACTH increased bilateral selectivity from 67% in the basal state to 92% 
post-stimulation. At the same time, discordance between basal and post-ACTH 
values was observed in 28% of patients, which were mostly lateralized cases under 
basal conditions that became bilateral post-ACTH. Therefore, ACTH stimulation may 
reduce the proportion of lateralized PA. We observed no significant differences in 
the post-surgical clinical outcomes of patients with unilateral PA diagnosed by AVS 
with an unstimulated protocol (n= 331) relative to patients diagnosed with an ACTH 
infusion protocol (n=374) (48). In our center, we generally perform bilateral 
simultaneous AVS without ACTH stimulation.  ACTH stimulation is restricted to 
specific situations:  for example, if patients are at risk of an allergic reaction to the 
anesthetic, if AVS is performed in the afternoon and if patients receive chronic low-
dose synthetic glucocorticoid treatment (i.e., 5 mg prednisolone/day).  
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The recently published SPARTACUS trial studied in a randomized fashion whether CT 
imaging based subtype determination was equivalent to AVS based decision making 
(49). The primary outcome of the study was the intensity of antihypertensive 
medication measured as defined daily drug dose (DDD) one year after initiation of 
specific treatment. Outcomes were essentially similar: the median DDDs of 92 
patients receiving CT-based treatment (in 46 adrenalectomy and in 46 MRA 
treatment) was 3·0 versus 3·0 in those receiving AVS-based treatment (46 
adrenalectomies and 46 treated by MRA, p=0·53). In the surgical groups, target 
blood pressure was reached in 39 (42%) patients and 41 (45%) of the operated 
patients, respectively (p=0·82). Additional secondary endpoints, such as health-
related quality of life or biochemical remission (80% versus 89%, p=0.25), were not 
different. Details of the study and perceived weaknesses in its design and 
methodology have been discussed in an unprecedented and ongoing flood of 
commentaries (50-53) splitting the community into those who were for or against 
AVS. The emotions arising from the study are in part due to the trial highlighting that 
a sophisticated procedure such as AVS is not 100% accurate, having a failure rate of 
approximately 5% (48), and that CT based management might be better than 
previously thought. As a consequence of this debate centers who used AVS for 
therapeutic decision making will continue to do so but will likely exempt young 
patients with imaging-positive adenomas. Centers without access to AVS will base 
their decision making with increased confidence on CT imaging, acknowledging that 
this strategy might have a failure rate of up to 20% (49).  
 
Treatment 
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The underlying cause of PA determines the appropriate treatment, surgical or 
medical management. For patients with unilateral PA, adrenalectomy offers the 
possibility of blood pressure remission or clinical improvement and the resolution of 
excess aldosterone production. In an international cohort study, unilateral 
adrenalectomy normalized blood pressure in 37% of 705 patients with PA and 
substantially improved the clinical outcome (blood pressure and antihypertensive 
medication response) in a further 47% (48). A successful biochemical outcome 
(correction of hypokalemia- if present pre-surgery- and normalization of the ARR) 
was achieved in 94% of 699 patients (48).  
 
Patients with bilateral PA are most effectively treated medically with an MR 
antagonist, usually spironolactone (54). Other patients included in this category are 
those with unilateral PA who opt for medical rather than surgical management or 
those who are unfit for surgery. Cases of spontaneous complete biochemical 
remission have been reported in patients with bilateral PA after long-term treatment 
with MR antagonists in (2 of 37 patients treated with spironolactone [5.4%] at 10.8 
and 12.9 years following diagnosis (55)] and in patients following long-term 
treatment with potassium canrenoate (56).  
 
Spironolactone is a competitive inhibitor of aldosterone for its receptor, the MR. It is 
non-selective and displays both antagonist activity to the androgen receptor and 
agonist activity to the progesterone receptor. The non-selective action of 
spironolactone can cause the associated adverse effects including gynecomastia, 
erectile dysfunction and menstrual irregularities. The incidence of gynecomastia 
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increases from <6.9% at a dose of <50 mg/day to 52% at >150 mg/day (57). 
Eplerenone is a selective MR antagonist that has no adverse effects but displays 
lower efficacy and high cost compared with spironolactone (58, 59). In Japan,  
eplerenone is approved for the treatment of hypertension, in the US and in Europe, 
for the treatment of congestive heart failure after a myocardial infarction. 
 
A longitudinal study that included 602 patients with PA (treated with a MR 
antagonist) compared with 41,853 age-matched patients with essential hypertension 
treated conventionally demonstrated a significantly higher rates of cardiovascular 
events independent of blood pressure control in the PA group (60). Patients with PA 
also had higher adjusted risks for incident mortality, diabetes, and atrial fibrillation. 
The excess risk for cardiovascular events and mortality was limited to patients with 
PA whose renin activity remained suppressed (<1 μg/L per h) on MR antagonists. The 
study suggests that titrating the increase in plasma renin activity as a response to 
MR antagonist therapy instead of blood pressure control would be a more effective 
therapeutic approach to avoid the excess cardiovascular risk associated with PA (60). 
The PAPY study analysed long-term cardiovascular outcomes and mortality in 1125 
patients screened for PA and treated according to biochemical results: unilateral 
adrenalectomy (4.8%) in patients with APA, MR antagonist treatment (6.4%) in 
patients with BAH and standard medical treatment in the remaining 88.8% with 
essential hypertension. After a median of 11.2 years overall survival was similar in 
patients treated for PA and for essential hypertension. MR antagonist treatment but 
not adrenalectomy was associated with a higher risk of atrial fibrillation (61). In 
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summary, both studies raise the question of uptitrating the dose of MR antagonists 
to block the MR more effectively and reduce long-term complications. 
 
Genetic forms of PA 
A number of somatic mutations have been identified in ion channels and 
transporters that drive the aldosterone excess in patients with APAs (62, 63). No 
clinical application has been firmly established although a potential future use may 
lie in steroid profiling to circumvent AVS in patients with bilateral disease by 
selection of those patients with a high probability of having an APA (64) or by 
selecting patients with an APA carrying KCNJ5 mutations using macrolide antibiotics 
as selective inhibitors (65).  
 
Germline variants have also been identified that cause rare familial forms of PA (62, 
63). The invasive procedure of AVS is unnecessary in patients with Familial 
Hyperaldosteronism types I and III (FH type I and FH type III) (66, 67) because the 
former is effectively treated with glucocorticoids (such as dexamethasone) and the 
latter is treated by bilateral adrenalectomy or with MR antagonists. Therefore, in 
accordance with the ES Society Guideline (3), genetic testing is recommended in 
patients with a diagnosis of early-onset PA (< 20 years old) or with a family history of 
PA or stroke at a young age (< 40 years) for the presence of the hybrid 
CYP11B1/CYP11B2 gene that causes FH type I (66) and in very young patients with a 
diagnosis of PA (for example, < 20 years) for germline mutations in the KCNJ5 gene 
that cause FH type III (68). Genetic testing of patients in these target groups offers 
the possibility of an early diagnosis of asymptomatic relatives and provides timely 
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treatment when appropriate. AVS should be performed in patients with Familial 
Hyperaldosteronism types II and IV (69-71) because these patients have been 
treated successfully by unilateral adrenalectomy as well as with MR antagonists (62).  
Germline heterozygous mutations in the voltage-gated chloride channel CIC-2, 
encoded by the CLCN2 gene, have been identified in families with FH-II and in 
patients with sporadic childhood-onset primary aldosteronism (72, 73). CIC-2 is 
expressed in adrenal glomerulosa cells, and the mutated channels show gain-of-
function with increased chloride conductance at resting potentials resulting in 
increased expression of aldosterone synthase and aldosterone secretion. These 
findings establish CLCN2 mutations as a cause of early-onset primary aldosteronism. 
 
Conclusions 
Since the publication of the ES guideline on primary aldosteronism in 2016, several 
high quality reports have advanced our knowledge of the genetics, diagnosis, 
subtype differentiation and treatment of PA. In general, these data confirm the 
diagnostic and therapeutic algorithm of the guideline. An exception is the 
SPARTACUS study but an independent trial which takes into account the criticisms of 
the many commentaries will resolve the issue of the validity of the results. In 
addition, novel functional imaging methods of PA, such as CXCR4 PET-CT imaging 
(74), could offer an alternative to ease the subtyping of PA. In summary, 
accumulating evidence highlights the importance of an early diagnosis and indicates 
that specific treatments can minimize or reverse the adverse effects of aldosterone 
excess. However, simplified procedures are required to enable timely, cost-effective 
and patient-friendly screening and diagnosis for PA. 
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Figure 1 Flow chart for the diagnostic workup of primary aldosteronism 
* Please refer to Table 1 for patients with hypertension to be screened for PA 
ADX, adrenalectomy; CT, computer assisted tomography; MR, mineralocorticoid 
receptor; PA, primary aldosteronism 
 
Figure 2 Differentiation of Unilateral from Bilateral forms of Primary Aldosteronism 
by Adrenal Venous Sampling 
 
Adrenal venous sampling is performed according to a defined standardized protocol 
in patients with confirmed PA after withdrawal of interfering medication (see text for 
details). Adrenal veins are sequentially catheterized via the femoral veins and blood 
is sampled from the inferior vena cava and from the right and left adrenal veins. The 
success of catheterization of each adrenal vein is indicated by the selectivity index 
(Tables 3-4) that can be determined by a rapid onsite cortisol assay (41-43). Plasma 
aldosterone and cortisol concentrations are measured in all blood samples. Adrenal 
venous plasma aldosterone concentrations are corrected for any dilution by blood 
from the inferior phrenic vein (on the left side) or from the inferior vena cava (on the 
right side) by dividing by the respective plasma cortisol concentrations (aldosterone-
to-cortisol ratios). The measurements of aldosterone and cortisol are used to derive 
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 RISK GROUPS RECOMMENDED TO BE SCREENED FOR PRIMARY ALDOSTERONISM 
ACCORDING TO ES GUIDELINE 
Patients with sustained blood pressure above 150/100 mmHg, grade 2 and 
grade 3 hypertension 
Patients with resistant hypertension (blood pressure not controlled by 3 
conventional drugs including a diuretic) or controlled BP (<140/90 mm Hg) on 
four or more antihypertensive drugs 
Patients with hypertension and spontaneous or diuretic induced hypokalemia 
Patients with hypertension and an adrenal incidentaloma 
Patients with hypertension and sleep apnea 
Patients with hypertension and a family history of early-onset hypertension or 
cerebrovascular accident at a young age (< 40 years) 
All first degree relatives of patients with PA 
 
 
Table 1 Screening for primary aldosteronism  
 
Includes data from Funder JW et al. (3) and Stowasser M & Gordon RD (20) 
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 CONFIRMATORY 
TEST 
DIAGNOSTIC CUT OFF VALUES 
Saline Infusion Test 
(SIT) 
PAC > 5-10 ng/dL (140-280 pmol/L) 
Oral Salt Loading 
Test (SLT) 
uAldo > 12 µg/24h (33 nmol/d)* or  
> 14 µg/24h (39 nmol/24h)† 
Fludrocortisone 
Suppression 
Test (FST)  
Upright PAC > 6 ng/dL (170 pmol/L) on day 4 at 10 am 
with PRA < 1 ng/mL/h and plasma cortisol less than the 
value at 7 am‡ 
Captopril Challenge 
Test (CCT) 
Decrease in PAC ≤ 30% (or ARR > 200 pg/mL/ng/mL/h)** 
 
Table 2 Confirmatory testing for primary aldosteronism 
 
PAC, plasma aldosterone concentration; PRA, plasma renin activity; uAldo, urinary 
aldosterone  
 
* At the Mayo clinic;  
† At the Cleveland clinic;  
‡ To exclude any confounding effect of ACTH.  
** Decrease in PAC ≤ 30% as defined by the ES Guideline (3) and ARR > 200 
pg/mL/ng/mL/h by the Japan ES Guidelines (23). 
 
Protocols describing confirmatory testing in detail are described in Stowasser and 
Gordon (20) 
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Unstimulated SI ≥ 2 LI ≥ 4 
Torino Unstimulated + 
continuous ACTH 
infusion 
SI ≥ 3 LI ≥ 4 or  
LI ≥ 3 and CLR ≤ 1 
Brisbane Unstimulated SI ≥ 3 LI ≥ 2.5 and CLR ≤ 1 
Rochester Continuous ACTH 
infusion 
SI ≥ 5 LI ≥ 4 
Sendai Bolus ACTH infusion SI ≥ 5 LI ≥ 2.6 
Yokohama 
City 
Bolus + continuous 
ACTH infusion 
[Cortisol]AV  
> 200 µg/dL* 
[PAC]ipsilateralAV  
> 1,400 ng/dL* 
 
Table 4 Different protocols and interpretation of adrenal venous sampling  
 
ACTH, adrenocorticotropic hormone; AVS, adrenal venous sampling; LI, lateralization 
index; PA, primary aldosteronism; PAC, plasma aldosterone concentration; SI, 
selectivity index. *In accordance with the Japan ES Guidelines (23) 
 
Includes data from Williams TA, et al. (48) 
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